{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-24-000025","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.446111+00:00","generated_at":"2026-06-06T04:23:06.550972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402","bullets":["Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.","IMVT-1402 Phase 1 showed 74% IgG reduction with no/minimal albumin or LDL changes vs placebo.","Plans to start 4-5 potentially registrational IMVT-1402 programs by Mar 2025, 10 indications by Mar 2026.","Batoclimab Phase 3 MG data expected 2H 2024; TED data 1H 2025; Phase 2b CIDP data 2Q/3Q 2024.","R&D spend $48.3M in Q3, up from $42.3M, driven by IMVT-1402 development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-24-000025","json":"https://secwatch.observer/filing/0001764013-24-000025.json","markdown":"https://secwatch.observer/filing/0001764013-24-000025.md","text":"https://secwatch.observer/filing/0001764013-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/imvt-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:23:06.550972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2036aeb569b29c24c628c1ab92240c9a90b6abef","claim":"Immunovant, Inc. reported the fiscal third quarter ended December 31, 2023 results: net income Net loss was $51.4 million ($0.36 per common share), EPS $0.36 per common share.","evidence_excerpt":"Net loss was $51.4 million ($0.36 per common share) for the three months ended December 31, 2023, compared to $63.2 million ($0.49 per common share) for the three months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss was $51.4 million ($0.36 per common share)"},{"label":"EPS","value":"$0.36 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"37b05232acfd5e6bd3556145a6220100f66ff0c8","claim":"Immunovant, Inc. reported the fiscal nine months ended December 31, 2023 results: net income Net loss was $184.0 million ($1.36 per common share), EPS $1.36 per common share.","evidence_excerpt":"Net loss was $184.0 million ($1.36 per common share) for the nine months ended December 31, 2023, compared to $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal nine months ended December 31, 2023"},{"label":"Net income","value":"Net loss was $184.0 million ($1.36 per common share)"},{"label":"EPS","value":"$1.36 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}